ECLAT
Phase 2 Withdrawn
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Phase 2 Withdrawn
LYMPHOSYNCHRO
Withdrawn
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
Phase 1/2 Withdrawn
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Phase 1 Withdrawn
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1 Withdrawn
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Phase NA Withdrawn
FIL_POLARDHAP
Phase 2 Withdrawn
CAR19T2
Phase 1/2 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
LEO
Withdrawn
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Phase 2 Withdrawn
SABRE
Phase 2 Withdrawn
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
Phase 1 Withdrawn
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
Phase NA Withdrawn
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Phase 1/2 Withdrawn
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Collecting and Storing Blood Samples From Patients With Cancer
Withdrawn
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Phase 1/2 Withdrawn
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Phase 1/2 Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
CD19-targeting CAR T Cells for B Cell Lymphoma
Phase 1/2 Withdrawn
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Phase 1 Withdrawn
Bone Marrow Transplantation in Treating Patients With Leukemia
Phase 3 Withdrawn
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Phase 2 Withdrawn
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
Phase 2 Withdrawn
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
Phase 1 Withdrawn
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
Phase NA Withdrawn
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase 1/2 Withdrawn
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Phase 2 Withdrawn
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Withdrawn
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Phase 2 Withdrawn
Cardiac Fibrosis by CMR in Patients With Cancer
Withdrawn
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 2 Withdrawn
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Withdrawn
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Phase 1 Withdrawn
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
Phase NA Withdrawn
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase 1/2 Withdrawn
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Phase 1/2 Withdrawn
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
Phase 2 Withdrawn
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Phase 2 Withdrawn
DETECS
Withdrawn
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Phase 1/2 Withdrawn
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Phase NA Withdrawn
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 2 Withdrawn
LYMPHOS
Phase 4 Withdrawn